As recently reviewed (3), virtually all subunit or viral vectored candidate TB vaccines tested clinically rest on a hypothesis that CD4+ T cell (and in some cases CD8+ T cell) induction of interferon-gamma (IFN-γ) is a host determinant of protection. The gene discussed is IFNG; the disease is tuberculosis.